الديناميكيات الدوائية للسبيرونولاكتون
مراجع

↑  Kenneth L. Becker (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. ص. 708, 777, 1087, 1196. ISBN:978-0-7817-1750-2. مؤرشف من الأصل في 2014-06-28. Spironolactone has been used successfully in dosages of 100 to 200 mg daily for the treatment of idiopathic hirsutism and hirsutism associated with polycystic ovarian disease (see Chaps. 96 and 101).184 [...] Spironolactone also is both an antiandrogen and a progestagen, and this explains many of its distressing side effects; decreased libido, mastodynia, and gynecomastia may occur in 50% or more of men, and menometrorrhagia and breast pain may occur in an equally large number of women taking the drug.27
1 2 3 4 5 6  Sabbadin C، Andrisani A، Zermiani M، Donà G، Bordin L، Ragazzi E، Boscaro M، Ambrosini G، Armanini D (2016). "Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI". J. Endocrinol. Invest. ج. 39 ع. 9: 1015–21. DOI:10.1007/s40618-016-0466-0. PMID:27072668.
↑  Levy J، Burshell A، Marbach M، Afllalo L، Glick SM (مارس 1980). "Interaction of spironolactone with oestradiol receptors in cytosol". J. Endocrinol. ج. 84 ع. 3: 371–9. DOI:10.1677/joe.0.0840371. PMID:7391714.
1 2  McMullen GR، Van Herle AJ (ديسمبر 1993). "Hirsutism and the effectiveness of spironolactone in its management". J. Endocrinol. Invest. ج. 16 ع. 11: 925–32. DOI:10.1007/BF03348960. PMID:8144871.
↑  Delyani، John A (2000). "Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology". Kidney International. ج. 57 ع. 4: 1408–1411. DOI:10.1046/j.1523-1755.2000.00983.x. ISSN:0085-2538. PMID:10760075.
↑  Pelkonen O، Mäenpää J، Taavitsainen P، Rautio A، Raunio H (1998). "Inhibition and induction of human cytochrome P450 (CYP) enzymes". Xenobiotica. ج. 28 ع. 12: 1203–53. DOI:10.1080/004982598238886. PMID:9890159. مؤرشف (PDF) من الأصل في 2015-09-24.
1 2  Rigalli JP، Ruiz ML، Perdomo VG، Villanueva SS، Mottino AD، Catania VA (يوليو 2011). "Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells". Toxicology. ج. 285 ع. 1–2: 18–24. DOI:10.1016/j.tox.2011.03.015. PMID:21459122.
1 2  Lehmann JM، McKee DD، Watson MA، Willson TM، Moore JT، Kliewer SA (سبتمبر 1998). "The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions". J. Clin. Invest. ج. 102 ع. 5: 1016–23. DOI:10.1172/JCI3703. PMC:508967. PMID:9727070.
1 2  Christians U، Schmitz V، Haschke M (ديسمبر 2005). "Functional interactions between P-glycoprotein and CYP3A in drug metabolism". Expert Opin Drug Metab Toxicol. ج. 1 ع. 4: 641–54. DOI:10.1517/17425255.1.4.641. PMID:16863430.
↑  Cheng SC، Suzuki K، Sadee W، Harding BW (أكتوبر 1976). "Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria". Endocrinology. ج. 99 ع. 4: 1097–106. DOI:10.1210/endo-99-4-1097. PMID:976190.
1 2  Sica، Domenic A. (2005). "Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis". Heart Failure Reviews. ج. 10 ع. 1: 23–29. DOI:10.1007/s10741-005-2345-1. ISSN:1382-4147. PMID:15947888.
1 2  Maron BA، Leopold JA (2008). "Mineralocorticoid receptor antagonists and endothelial function". Curr Opin Investig Drugs. ج. 9 ع. 9: 963–9. PMC:2967484. PMID:18729003.
↑  Michelle A. Clark؛ Richard A. Harvey؛ Richard Finkel؛ Jose A. Rey؛ Karen Whalen (15 ديسمبر 2011). Pharmacology. Lippincott Williams & Wilkins. ص. 286, 337. ISBN:978-1-4511-1314-3. مؤرشف من الأصل في 2020-04-15.
↑  Juruena MF، Pariante CM، Papadopoulos AS، Poon L، Lightman S، Cleare AJ (2013). "The role of mineralocorticoid receptor function in treatment-resistant depression". J. Psychopharmacol. (Oxford). ج. 27 ع. 12: 1169–79. DOI:10.1177/0269881113499205. PMID:23904409.
1 2  Agusti، Géraldine؛ Bourgeois، Sandrine؛ Cartiser، Nathalie؛ Fessi، Hatem؛ Le Borgne، Marc؛ Lomberget، Thierry (2013). "A safe and practical method for the preparation of 7α-thioether and thioester derivatives of spironolactone". Steroids. ج. 78 ع. 1: 102–107. DOI:10.1016/j.steroids.2012.09.005. ISSN:0039-128X. PMID:23063964.
↑  International Agency for Research on Cancer؛ World Health Organization (2001). Some Thyrotropic Agents. World Health Organization. ص. 325–. ISBN:978-92-832-1279-9. مؤرشف من الأصل في 2020-04-15.
↑  Pere Ginés؛ Vicente Arroyo؛ Juan Rodés؛ Robert W. Schrier (15 أبريل 2008). Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. John Wiley & Sons. ص. 229, 231. ISBN:978-1-4051-4370-7. مؤرشف من الأصل في 2020-04-15. The most rational treatment of cirrhotic patients with ascites appears to be the administration of an aldosterone antagonist. A stepwise equential therapy with increasing oral doses of an aldosterone antagonist (up to 400 mg/day) may be effective in mobilizing ascites in 60-80% of non-azotemic cirrhotic patients with ascites who do not respond to bed rest and dietary sodium restriction (11,12,74). The effective dosage of aldosterone antagonists depends on plasma aldosterone levels (75). Patients with moderately increased plasma levels require low doses of those drugs (100-150 mg/day), whereas patients with marked hyperaldosteronism may require as much as 200-400 mg/day. A further increase of the dosage up to 500-600 mg/day is of limited usefulness (11,12).
1 2 3 4 5  Corvol P، Michaud A، Menard J، Freifeld M، Mahoudeau J (يوليو 1975). "Antiandrogenic effect of spirolactones: mechanism of action". Endocrinology. ج. 97 ع. 1: 52–8. DOI:10.1210/endo-97-1-52. PMID:166833. مؤرشف من الأصل في 2020-04-15.
↑  Donald W. Seldin؛ Gerhard H. Giebisch (23 سبتمبر 1997). Diuretic Agents: Clinical Physiology and Pharmacology. Academic Press. ص. 630–632. ISBN:978-0-08-053046-8. مؤرشف من الأصل في 2014-07-04. The incidence of spironolactone in men is dose related. It is estimated that 50% of men treated with ≥150 mg/day of spironolactone will develop gynecomastia. The degree of gynecomastia varies considerably from patient to patient but in most instances causes mild symptoms. Associated breast tenderness is common but an inconsistent feature.
1 2  Loriaux، D. Lynn (نوفمبر 1976). "Spironolactone and endocrine dysfunction". Annals of Internal Medicine. ج. 85 ع. 5: 630–6. DOI:10.7326/0003-4819-85-5-630. PMID:984618.
↑  Cutler GB، Pita JC، Rifka SM، Menard RH، Sauer MA، Loriaux DL (1978). "SC 25152: A potent mineralocorticoid antagonist with reduced affinity for the 5 alpha-dihydrotestosterone receptor of human and rat prostate". J. Clin. Endocrinol. Metab. ج. 47 ع. 1: 171–5. DOI:10.1210/jcem-47-1-171. PMID:263288.
↑  Yamasaki K، Sawaki M، Noda S، Muroi T، Takakura S، Mitoma H، Sakamoto S، Nakai M، Yakabe Y (2004). "Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals". Toxicology. ج. 195 ع. 2–3: 177–86. DOI:10.1016/j.tox.2003.09.012. PMID:14751673.
1 2  Eil C، Edelson SK (يوليو 1984). "The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors". J. Clin. Endocrinol. Metab. ج. 59 ع. 1: 51–5. DOI:10.1210/jcem-59-1-51. PMID:6725525.
↑  Pita JC، Lippman ME، Thompson EB، Loriaux DL (ديسمبر 1975). "Interaction of spironolactone and digitalis with the 5 alpha-dihydrotestosterone (DHT) receptor of rat ventral prostate". Endocrinology. ج. 97 ع. 6: 1521–7. DOI:10.1210/endo-97-6-1521. PMID:173527.
↑  Liang T، Rasmusson GH، Brooks JR (يوليو 1983). "12. Androgens: Pharmacodynamics and antagonists. Biochemical and biological studies with 4-aza-steroidal 5 alpha-reductase inhibitors". J. Steroid Biochem. ج. 19 ع. 1A: 385–90. DOI:10.1016/s0022-4731(83)80051-x. PMID:6887871.
↑  Hammerstein، J. (1990). "Antiandrogens: Clinical Aspects". Hair and Hair Diseases. ص. 827–886. DOI:10.1007/978-3-642-74612-3_35. ISBN:978-3-642-74614-7.
↑  Hecker A، Hasan SH، Neumann F (ديسمبر 1980). "Disturbances in sexual differentiation of rat foetuses following spironolactone treatment". Acta Endocrinol. ج. 95 ع. 4: 540–5. DOI:10.1530/acta.0.0950540. PMID:7456979.
↑  Di Lorenzo G، Autorino R، Perdonà S، De Placido S (ديسمبر 2005). "Management of gynaecomastia in patients with prostate cancer: a systematic review". Lancet Oncol. ج. 6 ع. 12: 972–9. DOI:10.1016/S1470-2045(05)70464-2. PMID:16321765.
بوابة المرأة
بوابة صيدلة